Search

Displaying results 4261 - 4270 of 10000 in total
  1. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim [L2939]. … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label].

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  2. Drug

    Perospirone

    go.drugbank.com/drugs/DB08922
    Investigational

    It is also shown to be less associated with extrapyramidal symptoms as a side effect compared to [DB00502]. … It is commonly present as the hydrated hydrochloride salt form.

    Categories: Dopamine D2 Receptor Antagonists
  3. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists
  4. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  5. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    It has been approved for the treatment of insomnia.

    Categories: Orexin Receptor Antagonists
  6. Drug

    8-chlorotheophylline

    go.drugbank.com/drugs/DB14132
    Experimental

    Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation. … a number of effects including nervousness, restlessness, insomnia, headache, and nausea, which are primarily attributed to its ability to block the adenosine receptor [A33889, A1539].

  7. Drug

    Canrenoic acid

    go.drugbank.com/drugs/DB09015
    ApprovedInvestigationalWithdrawn

    Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

    Categories: Mineralocorticoid Receptor Antagonists
  8. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with … [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  9. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH

    Categories: Antidiuretic Hormone Receptor Antagonists, Vasopressin V2 Receptor Antagonist
  10. Drug

    Prednisolone

    go.drugbank.com/drugs/DB00860
    ApprovedInvestigationalVet approved

    Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

    Synonyms: Predniso(lo)neCategories: Corticosteroid Hormone Receptor Agonists